Last reviewed · How we verify
Leuvectin
At a glance
| Generic name | Leuvectin |
|---|---|
| Also known as | Interleukin-2 (IL-2) plasmid DNA/lipid complex |
| Sponsor | Vical |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001) (Phase 1)
- Phase II Study Evaluating the Safety and Efficacy of Neoadjuvant Leuvectin Immunotherapy for the Treatment of Prostate Cancer (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leuvectin CI brief — competitive landscape report
- Leuvectin updates RSS · CI watch RSS
- Vical portfolio CI